Sep 17, 2020

Reveal LINQ II™ Insertable Cardiac Monitor For Unexplained Fainting

Information about the Reveal LINQ II ICM designed to give physicians valuable insights that could help identify the cause of unexplained fainting.

The following media kits are made available to provide reporters with background information on the range of Medtronic therapies and the conditions they treat.

Jul 7, 2020
Next Generation ICM Offers Remote Programming with Improved Longevity and Enhanced Accuracy

DUBLIN, July 07, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) clearance and...

Mar 24, 2017
American College of Cardiology, American Heart Association and Heart Rhythm Society Jointly Issue First-Ever Syncope Guidelines that Reinforce Benefits of Continuous Cardiac Monitoring

DUBLIN - March 24, 2017 - Newly published guidelines from the American College of Cardiology (ACC), the American Heart Association (AHA), and the Heart Rhythm Society (HRS) recommend the use of...

Mar 26, 2012
ACC.12 Late-breaker Shows Promise of Pacemakers through Diminishing Fainting Recurrences in Patients Diagnosed with Syncope

MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Mar. 26, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the results of a double-blind, randomized study, ISSUE-3, which found that patients who suffered...

May 5, 2011

MINNEAPOLIS & SAN FRANCISCO, May 05, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced findings from the DISCERN AF trial, which utilized Medtronic's Reveal(R) XT insertable...

Nov 19, 2010
PICTURE Registry Results Published Online Today in EP-Europace

MINNEAPOLIS, Nov 19, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced the publication of data showing that use of its Reveal(R) family of Insertable Cardiac Monitors led to...

Sep 28, 2010
Reveal(R) Plus Study Results Published Today in Circulation

MINNEAPOLIS, Sep 28, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced the publication of results from a multicenter, prospective study that demonstrated that the company's Reveal(R)